A series of immune responses leading to the induction ofT cell IL-12/IL-18 responsiveness in patientswith relatively large tumor burdens

作者: Kazuko Uno , Yoko Mitsuishi , Mari Tanigawa , Kiyotaka Okuno , Norihiko Hirai

DOI: 10.1007/S00262-002-0329-8

关键词:

摘要: The induction of interleukin-12 (IL-12) responsiveness in T cells depends on cell receptor (TCR) triggering, and is regarded as a parameter recently TCR-sensitized cells. Here, we investigated whether IL-12 could be detected freshly prepared from tumor-bearing patients, if so such patients exhibited additional immunological parameters related to responsiveness. CD4+ CD8+ populations an appreciable proportion high levels evaluated by IL-12-stimulated interferon-gamma (IFN-γ) production. with were observed the group moderate large tumor mass or metastases rather than small tumors. frequency population was also lower post-surgery tumor-free showing correlation between presence certain extent burden. More importantly, higher incidence exhibiting detectable plasma levels, correlated IL-18 induced TCR triggering subsequent stimulation respectively. Furthermore, TCR-triggered stimulate antigen-presenting (APC) produce IL-12. Therefore, present observations suggest that immune response loop sensitization IL-12/IL-18 via production operates particularly those relatively burdens.

参考文章(33)
W Hashimoto, K Kumagai, R Anzai, K Ogasawara, K Takeda, S Seki, M Takahashi, M Satoh, K Sugiura, Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. Journal of Immunology. ,vol. 156, pp. 3366- 3373 ,(1996)
Wen-Gong Yu, Noriniko Yamamoto, Hiroshi Takenaka, Jie Mu, Xu-Guang Tai, Jian-Ping Zou, Makoto Ogowa, Tateki Tsutsui, Rishani Wijesuriya, Ryotaro Yoshida, Steven Herrmann, Hiromi Fujiwara, Toshiyuki Hamaoka, Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor growth inhibition induced during tumor immunotherapy with rIL-12 International Immunology. ,vol. 8, pp. 855- 865 ,(1996) , 10.1093/INTIMM/8.6.855
R Bukowski, K Sandstrom, A Rakhit, T Olencki, R J Motzer, R Nadeau, T M Malone, H Parmar, L H Schwartz, Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Research. ,vol. 4, pp. 1183- 1191 ,(1998)
Francesca Fallarino, Thomas F. Gajewski, Andrew Ashikari, Matthew Sherman, Immunization of HLA-A2+ Melanoma Patients with MAGE-3 or MelanA Peptide-pulsed Autologous Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin 12 Clinical Cancer Research. ,vol. 7, ,(2001)
Shinobu Imajoh-Ohmi, Hideo Nariuchi, Hidehiro Yamane, Osamu Igarashi, IL-12 Receptor (IL-12R) Expression and Accumulation of IL-12Rβ1 and IL-12Rβ2 mRNAs in CD4+ T Cells by Costimulation with B7-2 Molecules Journal of Immunology. ,vol. 160, pp. 1638- 1646 ,(1998)
A. O'garra, S. E. Macatonia, K. M. Murphy, P. Vieira, N. A. Hosken, M. Wysocka, Chyi-Song Hsieh, M. Litton, J. A. Culpepper, G. Trinchieri, Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. Journal of Immunology. ,vol. 154, pp. 5071- 5079 ,(1995)
Hiromi Fujiwara, Rishani Wijesuriya, Wen-Gong Yu, Toshiyuki Hamaoka, Steven Herrmann, Tateki Tsutsui, Jie Mu, Jian-Ping Zou, Makoto Ogawa, Takeshi Kubo, Enhanced Induction of Very Late Antigen 4/Lymphocyte Function-associated Antigen 1-dependent T-Cell Migration to Tumor Sites following Administration of Interleukin 12 Cancer Research. ,vol. 57, pp. 2216- 2222 ,(1997)
H Tahara, H D Edington, M J Brunda, S F Wolf, R D Schreiber, W J Storkus, M K Gately, M A Nalesnik, T G McKinney, C L Nastala, Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. Journal of Immunology. ,vol. 153, pp. 1697- 1706 ,(1994)
Jennifer B. Meko, Ying L. Tsung, Gary R. Peplinski, Kangla Tsung, Jeffrey A. Norton, Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. Journal of Immunology. ,vol. 160, pp. 1369- 1377 ,(1998)